EGFR and glioblastoma: The latest WHO classification adopts a multi-layer integrated approach to defining glioblastoma, integrating histological features with molecular signatures: IDH-1 mutation, EGFR amplification, TERT promoter mutations, and the combined gain of chromosome 7 and loss of chromosome 10 [80].